TaiRx, Inc.
- Biotech or pharma, therapeutic R&D
TaiRx is a pharmaceutical company dedicated to developing novel therapeutics, with a primary focus on oncology. Our pipeline includes CVM-1118, a first-in-class new chemical entity (NCE) for the treatment of various solid tumors, which has received Orphan Drug Designation (ODD) from the U.S. FDA for pancreatic neuroendocrine tumors (pNET). We are also advancing TRX-ADC, an antibody-drug conjugate with a novel payload for cancer treatment, and TRX-920, a new oral formulation of SN-38 for the treatment of colon cancer. In addition, TRX-105 is a preclinical-stage asset being developed for the treatment of inflammatory bowel disease (IBD).
TaiRx is actively seeking partnering and licensing opportunities to support the continued development and commercialization of these programs.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}